These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 2354435)

  • 1. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
    Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
    Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
    Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
    J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.
    Speiser P; Stolzlechner J; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeilliger R
    Anticancer Res; 1994; 14(5B):2125-30. PubMed ID: 7840511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
    Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
    Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
    Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
    Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.
    Thorpe SM; Rose C; Rasmussen BB; Mouridsen HT; Bayer T; Keiding N
    Cancer Res; 1987 Nov; 47(22):6126-33. PubMed ID: 3664512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.
    Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M
    Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
    Johnston SR; Saccani-Jotti G; Smith IE; Salter J; Newby J; Coppen M; Ebbs SR; Dowsett M
    Cancer Res; 1995 Aug; 55(15):3331-8. PubMed ID: 7614468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.
    Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G
    Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human breast cancer: survival from first metastasis. Breast Cancer Study Group.
    Koenders PG; Beex LV; Kloppenborg PW; Smals AG; Benraad TJ
    Breast Cancer Res Treat; 1992; 21(3):173-80. PubMed ID: 1515652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
    Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
    Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
    Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
    J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
    Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
    Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.
    Alexieva-Figusch J; Van Putten WL; Blankenstein MA; Blonk-Van Der Wijst J; Klijn JG
    Cancer; 1988 Feb; 61(4):758-68. PubMed ID: 3338038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.